Barcelona to Host a New Research Center Specialized in Immunology in 2024

Barcelona is a pioneer in health research. The Catalan city will host the CaixaResearch Institute in 2024, the first facility in Spain and one of the first in Europe dedicated to immunology, through a transversal approach between the different scientific and technological disciplines involved in the study of the immune system.

In addition, the center will pay special attention to innovation and the transfer of results to society. At CaixarResearch, research will be key to advancing knowledge and understanding of immune system processes and their role in global health and in infectious, oncological, and neurological diseases.

Following the approval of the urban planning procedures by the Barcelona City Council and the Generalitat de Catalunya, the Fundació la Caixa has continued to move forward to bring the project to fruition. The definition of the scientific plan and the infrastructures that will be required to address these challenges has been one of the main focuses of these first months of work.

Born2Invest mobile app makes it easy for you to keep informed, to intuitively move from story to story, and from section to section. Our clean design lets you read articles without clutter, and use the app with no limits on how many articles you can view. Get comprehensive access to global biotech business, stock market, finance news, and trending topics with the Born2Invest companion app. 

Barcelona will have the first research center in Spain dedicated to immunology

The building will have a total surface area of approximately 19,000 square meters and will have spaces and equipment for scientific activity, such as dry and wet laboratories, scientific-technical services and spaces for innovation, office areas for management, administration, and administration activities, and spaces for the reception and reception of visitors, where events, training and networking initiatives will be held.

The works of the future center will begin in June with a gradual demolition of the pre-existing building, on Manuel Ramon street, in front of CosmoCaixa, according to the foundation in an entity. The entity’s forecast is that in the second half of 2022 the construction of the building, whose architectural project is in charge of TAC Arquitectes, will begin.

Throughout 2023 the process of attracting and recruiting talent will begin; in 2024 the first spaces of the architectural complex will be opened, and in 2025 the construction and adaptation of the scientific spaces will be completed.

In 2021, the la Caixa Foundation, chaired by Isidro Fainé, dedicated more than 36 million euros to research and innovation projects in biomedicine and health that are carried out in research centers, universities, and hospitals in Spain and Portugal, where the entity collaborates with more than a hundred institutions.

__

(Featured image by Benjamin Gremler via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.